Product Name: DYRK2 (379-385) pY382
Product Number: PE-04ATC00
Size: 200 µg      Price:35.00
1 mg      $US71.00
Peptide Name: DYRK2 (379-385) pY382

Product Use: This phosphopeptide may be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. Y382 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: VYT-pY-IQS

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated
Peptide Purity Percent after Synthesis and Purification: >80

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Scientific Background: DYRK2 is a protein-serine/threonine kinase of the CMGC group and DYRK family. It is a dual-specificity protein kinase that regulates cell cycle progression, cell proliferation, apoptosis, cytoskeletal organization, and neurite outgrowth. DYRK2 functions downstream of ATM and directly phosphorylates p53/T53 at the S46 to promotion of apoptosis in the presence of DNA damage. In addition, DYRK2 functions in ubiquitin-dependent proteasomal protein degradation, specifically promoting the degradation of the oncoproteins in the Myc and Jun families. DYRK2 appears to be a tumour suppressor protein (TSP). Abnormal expression of DYRK2 have been associated with various forms of human cancer. In breast cancer cells, DYRK2 negatively regulates the stability of Snail, a transcription factor that regulates the epithelial-mesenchymal transistion (EMT). Knock-down of DYRK2 expression in breast cancer cells promotes EMT and tumour invasion both in vitro and in vivo. In addition, tumours with low expression of DYRK2 were correlated with a significantly lower patient survival and higher metastasis rate than tumours with high DYRK2 expression. Therefore, the DYRK2 protein appears to be a critical suppressor of cancer invasion and metastasis. Similarly, the 5-year survival rates of pulmonary adenocarcinoma patients was significant higher for those with DYRK2-positive tumours (89. 2%) than those with DYRK2-negative tumours (66. 3%), indicating a critical role for DYRK2 as a tumour suppressor in this cancer type as well.